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Abstract
The success of radiotherapy cancer treatment delivery depends on the accuracy of patient setup for each fraction. A significant
problem arises from reproducing the same patient position and prostate location during treatment planning for every fraction of
the treatment process. To analyze the daily movements of the prostate, gold markers are implanted in the prostate and portal
images taken and manually matched with reference images to locate the prostate. Geometrical and fiducial markers are anno-
tated onto a highly quality generated digitally reconstructed radiographs, that are compared with portal images acquired right
before treatment dose delivery. A 0 and 270 degree treatment fields are used to calculate prostate shifts for all prostate cancer
patients undergoing treatment at the Sweden Ghana Medical Centre, using an iViewGT portal imaging device. After aligning of
the marker positions onto the reference images, the set-up deviations corrections are displayed and an on-line correction pro-
cedure applied. The measured migrations of the prostate markers are below the threshold of 3 mm for the main plans and 2 mm
for the boost plans. With daily electronic portal imaging combined with gold markers, provides an objective method for verify-
ing and correcting the position of the prostate immediately prior to radiation delivery.
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Introduction
External beam radiation therapy is an effective method of
treating cancer, in which the lesion is irradiated with
high-energy beams produced by a linear accelerator. The goal
is to minimize the dose to normal tissue surrounding the
clinical target volume (CTV). Treatment techniques such as
three dimensional conformal radiotherapy (3DCRT) and
intensity modulated radiation therapy (IMRT) provide very
accurate radiation to the lesion, while sparing healthy tissues.
Radiation treatment always starts with the acquisition of
planning computerized tomographic (CT) images. CT data
play a central role in radiotherapy treatment planning (RTP).1
Efficacy of the RTP depends on the patient setup at each daily
fraction. The problem is to reproduce the patient position at
the time of acquiring the planning CT scans (used for RTP)
for each fraction of the treatment process. Discrepancies
between the planned and delivered treatment positions sig-
nificantly degrade the therapeutic ratio. The planning target
volume (PTV) is defined to include the CTV and associated
treatment uncertainties, which include but are not limited to
imaging, patient setup, and organ motion. Prostate motion,
defined as a positional change of the prostate at the time of
treatment relative to the planning position, has been evalu-
ated for different conditions and methods. Radiation oncolo-
gists are now required to be familiar with 3-dimensional
determination of gross tumour volume (GTV), clinical target
volume, and organs at risk. Setup error in CT simulation also
needs to be paid more attention, as recent studies pointed
out.2 However, it could be difficult for an oncologist to meet
these increasing requirements; hence, distant consultation is
expected to be useful in the management of patients. Sending
images needed for radiotherapy seems to be one means of
such consultation. Radio opaque markers, gold seeds, CT-CT
fusion, and CT chamfer matching are examples of methods
used to determine the prostate position relative to fixed bony
landmarks. The largest motion was observed to be in the
anterior/posterior (AP) direction and to a lesser extent in the
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superior/inferior (SI) direction. The AP movement was
strongly correlated with rectal filling and then to a lesser
extent with bladder filling.3 One of the conventional methods
to reduce patient setup error includes matching the skin
tattoo marks generated at the planning phase with the
treatment room laser lights. Immobilization devices such as
foam casts or thermoplastic masks are also used to assist in
reproducing the daily treatment position. These approaches
can fail to adequately ensure the location reproducibility,
since the positioning is done based on the outer surface of the
patient’s body.4 Adjustment of the patient setup can also be
achieved using internal anatomical landmarks identified on
portal images acquired with the patient in the treatment
position. Portal images can be acquired using an electronic
portal imaging device (EPID).1 Improper knowledge of the
patient’s anatomy and position during the course of therapy
has always been a major source of concern in radiation ther-
apy potentially compromising the clinical results by insuffi-
cient dose coverage of the target volume and/or over dosage
to normal tissues. The management of target localization
emanates in the concept of treatment margins, such as those
described in the ICRU reports 50 and 62.5, 6
A critical requirement in radiation therapy is accurate
day-to-day treatment setup. Early studies based on port films
indicated the benefits of portal verification.7 Precise imaging
and targeting of treatment targets for radiotherapy allows
dose escalation while avoiding toxicity of the surrounding
normal tissues. The aim of imaging for treatment verification
is to evaluate the geometric uncertainties both due to organ
motion and setup variations. Portal imaging using bony
structures can only detect set-up variations. If implanted
markers are used, both set-up variations and internal organ
motion can be detected and if necessary, corrected. Two types
of deviations have to be distinguished: the day-to-day (ran-
dom) variations and the systematic variations, present during
all treatment fractions.8 Both the set-up variations and the
organ motion have random and systematic components. The
use of gold markers for positioning verification has been
reported mainly for the irradiation of the prostate; investiga-
tions have started for head-and-neck, lung and liver.1
In prostate radiotherapy 3, 9, 10, the actual position of the
prostate can be visualized and verified by using gold markers.
In Sweden Ghana Medical centre (SGMC), so far, fiducial
gold markers are implanted in prostate cancer patients who
received external radiation therapy with 3D conformal ra-
diotherapy planning technique for treatment. Three fine gold
markers are inserted in the prostate under trans-rectal ultra-
sound guidance by an urologist. To verify the treatment po-
sition of the prostate using an iViewGT verification system,
portal images are acquired with an electronic portal imaging
device 4, 11, using the first 5 monitor units (MUs); 3MUs from
the lateral and 2MUs from posterior of the treatment beams.
The full standard configuration of an iViewGT portal imaging
device includes a flat panel image detection system with
powerful image processing and display, using industry stan-
dard IT hardware and software. To analyse patient and pros-
tate position variations, the marker contours derived from the
digitally reconstructed radiograph (DRR), are displayed
overlaying the portal image and manually matched as shown
in Figure 1.
In radiotherapy, a digitally reconstructed radiograph, which
is used for treatment verification in CT simulation, is one of
the important images which can be sent via telecommunica-
tion. Accurate and routine target localization is necessary for
successful outcome in radiation therapy treatments. Elec-
tronic portal imaging devices provide an advanced tool with
digital technology to improve target localization and main-
tain clinical efficiency. EPIDs are ubiquitous in the radiation
therapy clinic, and they provide a powerful and flexible tool
to collect and process data in a quantitative manner to im-
prove treatment accuracy for virtually any treatment site.12
FIG. 1: Gold markers (green) and bone structure (blue) annotations with the treatment fields.
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Radiation therapy can only be effective if the intended dose is
delivered as prescribed throughout the treatment course.
Taking the impact of each of these variations into account for
target localization is essential in providing the most accurate
radiation treatment. Although many mechanisms exist to
monitor and manage target positioning, the application of
electronic portal imaging devices is becoming a standard tool
for this purpose and is the focus of this article.13 At the plan-
ning stage a set of DRRs is generated from the CT scan of the
patient. This set of images is used as the reference, repre-
senting the ideal patient position at the time of treatment. At
the treatment stage a set of localization portal images is taken
at the same gantry angles as the reference images. Localiza-
tion and reference images are visually compared and corre-
sponding anatomical landmarks are identified in both sets.
The setup error is estimated and the patient position is cor-
rected to reduce the discrepancies between the localization
and reference images.
From the results, the random error in the prostate position,
derived from the gold markers, is defined as the standard
deviation of the day-to-day variations, averaged over all pa-
tients in the group. The systematic error is defined as the
standard deviation of the distribution of average prostate
deviations per patient. For inter-fraction prostate position
corrections, the so-called No Action Level (NAL) off-line
protocol can be used. With this protocol the systematic errors
can be reduced, with a minimum of extra workload and
hardly any extra treatment time necessary on the accelerator.
The deviations are measured and corrected after the third
treatment fraction. To correct both systematic and random
errors, an on-line correction procedure is applied.14 Set-up
deviations in lateral, longitudinal and vertical directions are
corrected and checked again, before the irradiation.
Overall, the measured migrations of the prostate markers are
expected to be in a threshold of 3 mm for the main plan and
2mm for the boost plan. The results (in mm) are prostate
position relative to isocenter systematic deviation and the
shifts are isocenter shifts not couch shifts. Implanted fiducial
markers allow detection and correction of organ and/or tu-
mour specific position variations. This image guided radio-
therapy procedure with gold markers and the EPID has re-
sulted in accurate high-dose, high-precision prostate treat-
ments, with less toxicity to the bladder and rectum. De-
pending on accuracy requirements, off-line correction pro-
tocols appear to be effective in reducing systematic deviations
at an acceptable workload. With on-line corrections a very
high geometric accuracy (<3 mm) can be obtained, but at the
cost of a considerably larger effort.
Conclusion
Prostate is known to move independently of bony landmarks
requiring additional effort to visualize its position prior to
radiation delivery. The use of implanted markers and elec-
tronic portal imaging has become the gold standard for daily
verification of position and correction of patient setup and
organ displacement errors.15 Improving geometric accuracy
through image guided therapy in radiation treatment delivery
can reduce the volume of normal tissue irradiated. There are
various analysing methods to quantitatively assess the geo-
metric gains from IGRT. One application of IGRT at SGMC
involves implanting gold markers in prostate cancer patient
irradiation setup. An EPID imaging method is used to bring
the treatment fields into alignment with a reference DRR
images. This method assumes a high degree of correlation
between the prostate target and reference target location in
real time. This reduction in errors due to target motion per-
mits the use of high precise doses to the target, which in turn
reduce dose to normal tissues. The gain in IGRT is realized by
acquiring port film setup images on a daily basis to ensure
appropriate field placement. Daily electronic portal imaging
combined with gold markers provides an objective method to
verify and correct the position of the prostate immediately
prior to radiation delivery. Its routine clinical use can im-
prove the precision of external beam radiation therapy in the
treatment of prostate cancer.16, 17A total of 5 monitor units are
used for imaging of these open isofields daily or 5 monitor
units subtracted from the treatment fields.
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